Joel Dore
@dorejoel
Followers
1K
Following
606
Media
40
Statuses
2K
Research Director at INRA https://t.co/DTbNf3jVJa and https://t.co/LXoTOushbK, co-founder and scientific advisor of the startup https://t.co/zvIZSHgN8L.
Jouy-en-Josas, France
Joined March 2011
Struggling to keep updated on the most relevant science on gut microbiome, probiotics, and prebiotics? Then you might enjoy our newsletters: https://t.co/2CwW7GE86x
0
1
4
Season 5 is going to start soon! Check out the program and feel free to join the keynotes by presenting your work–abstract submission is open: https://t.co/i6eJcbnbte
1
10
26
Increased dietary fiber intake, through its interaction with the gut microbiota, may help prevent type 2 diabetes Why slowly fermented, intrinsic plant cell fibers may improve metabolic health: https://t.co/34JokwHUZR
0
4
9
Microbiome tests are becoming popular to diagnose and manage microbiome-related conditions A new consensus involving scientists in basic and translational science updates the ins and outs of microbiome testing in clinical practice: https://t.co/W0rkHKx3dl
gutmicrobiotaforhealth.com
A new consensus involving scientists in basic and translational science updates the ins and outs of microbiome testing in clinical practice.
0
3
8
Et si la recherche sur le #microbiote intestinal devenait un thriller ? Dans Mission : Microbiome, @veiga_pat mêle science et fiction pour explorer comment les microbes influencent notre santé. Découvrez l’envers du récit scientifique dans cette interview https://t.co/Y2HvdmQC21
gutmicrobiotaforhealth.com
Le microbiome humain suscite l’intérêt des chercheurs et des particuliers. Des premiers probiotiques aux innovations révolutionnaires promises à transformer l’avenir de la médecine et de la nutriti...
0
3
6
[Communiqué de Presse] – Nous sommes fiers d’annoncer la signature d’un accord exclusif à long terme avec Clinigen pour la licence, la distribution et la commercialisation de notre candidat médicament le plus avancé, Xervyteg® (MaaT013), destiné aux patients atteints de la
0
3
7
The microbiome is knocking on the clinicians' door @gianluca1aniro, @Siew_C_Ng, @GiovanniCammar9, @h_sokol, @EranElinav @Elinav_Lab @WeersmaLab & colleagues update key microbiome findings ripe to bedside and challenges: https://t.co/ajBwaxj3DG
1
8
35
📄 [Communiqué de Presse] - MaaT Pharma présente les résultats de son Assemblée Générale ordinaire annuelle et extraordinaire. 👉 Consultez le communiqué de presse ici : https://t.co/eL6Zm6sPZj
#AssembléeGénéraleAnnuelle #AG2025 #Business #Actionnaires
0
1
1
📰 [#Média] - MaaT Pharma à l’honneur dans @LaTribune ! Merci à Anne Taffin pour cet article qui revient sur notre demande d’autorisation de mise sur le marché auprès de l’@EMA pour Xervyteg® (MaaT013), notre candidat-médicament le plus avancé dans le traitement de la maladie
0
3
3
Understanding the health impacts of local, culturally relevant diets will be critical to advancing precision nutrition This timely editorial in @NatureMedicine is worth reading for all researchers in nutrition & microbiome: https://t.co/Teetj0OJP0
nature.com
Nature Medicine - Understanding the health impacts of local, culturally relevant diets will be critical to advancing precision nutrition across diverse populations in a sustainable way.
0
2
8
📢 𝗪𝗼𝗿𝗹𝗱 𝗜𝗕𝗗 𝗗𝗮𝘆 - Another key study just dropped and it confirms the superiority of multidonor product over mono donor ones in Ulcerative Colitis! A new paper recently published in 𝘛𝘦𝘤𝘩𝘯𝘪𝘲𝘶𝘦𝘴 𝘪𝘯 𝘊𝘰𝘭𝘰𝘱𝘳𝘰𝘤𝘵𝘰𝘭𝘰𝘨𝘺, one of the @SpringerNature
0
2
2
Maternal gut microbiota influences immune activation at the maternal-fetal interface affecting pregnancy outcome @maria_rescigno et al. suggest that targeting the gut microbiota may offer a strategy for preventing preeclampsia: https://t.co/7om8TTzXxM
nature.com
Nature Communications - Preeclampsia is a leading cause of morbidity and mortality in pregnancy and has multiple causes. Here the authors examine how changes in the gut microbiota alter pregnancy...
1
6
20
Highlights from the #GMFH2025 Summit! Experts shared the latest in #microbiome research for diagnosing, preventing & managing GI and extra-intestinal conditions. 🔬 From new diagnostics to personalized care—don’t miss the key takeaways by @andreuprados
https://t.co/wTwVWRKjSZ
0
5
16
🎥 Dans cette interview, Hervé Affagard, notre CEO et co-fondateur, revient sur les annonces majeures de ce début d’année, notamment les résultats positifs de l’essai de Phase 3 évaluant MaaT013 dans l’aGvH et les prochaines étapes clés de développement de MaaT Pharma. 🎥 In
0
4
7
📄 [Communiqué de Presse] - MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA) ✅L’essai a atteint son critère principal de sécurité et de tolérabilité ✅Implantation rapide et soutenue
0
1
3
Postbiotic supplementation may offer some benefits on inflammation, oxidative stress, and clinical outcomes in patients with background cerebrovascular accidents Read the full clinical trial: https://t.co/2Iq3w96LEI
nature.com
Scientific Reports - Clinical trial of the effects of postbiotic supplementation on inflammation, oxidative stress, and clinical outcomes in patients with CVA
0
9
22
📰 [Press release] –MaaT Pharma Stock Initiated with "Buy" Rating by H.C. Wainwright & Co., Target Price Set at €21 @HCWCO 👉Read the press release here: https://t.co/bpzm28GLtJ
#Stock #InvestorRelations #Analysts #Biotech #Investing #Finance #BiotechStocks
0
2
2
Microplastic pollution can be detrimental to human, animal, and environmental health Why microplastic research must consider the microbiome: https://t.co/CeLy6HAI4q
nature.com
Nature Microbiology - It is increasingly clear that microplastic pollution can be detrimental to human, animal and environmental health. More research is needed to determine if and how our...
0
3
9
MaaT Pharma : conclusion positive de l'examen final du DSMB pour l'essai clinique pivotal de Phase 3 évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte https://t.co/TFSu6y0vmA
#bourse #finance $MAAT
boursier.com
Démonstration
0
3
4
📅 - [#Event] – Meet Jonathan Chriqui, Chief Business Officer at MaaT Pharma, at #BIOEurope Spring, on March 17-19, 2025, in Milan, Italy. We are eager to connect with global life science leaders and explore new collaboration opportunities. MaaT Pharma is actively seeking to
0
2
2